Published in Ann Rheum Dis on January 05, 2006
Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov (2012) 4.40
Targeting interleukin-1 in heart disease. Circulation (2013) 2.52
Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis (2008) 2.33
Inhibition of interleukin-1β decreases aneurysm formation and progression in a novel model of thoracic aortic aneurysms. Circulation (2014) 2.28
The expanding family of interleukin-1 cytokines and their role in destructive inflammatory disorders. Clin Exp Immunol (2007) 2.22
Treating inflammation by blocking interleukin-1 in humans. Semin Immunol (2013) 1.75
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis (2007) 1.70
The acute pulmonary inflammatory response to the graded severity of smoke inhalation injury. Crit Care Med (2012) 1.62
The NLRP3 inflammasome in health and disease: the good, the bad and the ugly. Clin Exp Immunol (2011) 1.56
Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence. Am J Ophthalmol (2008) 1.56
Challenges and approaches for the development of safer immunomodulatory biologics. Nat Rev Drug Discov (2013) 1.35
Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study. Clin Rheumatol (2008) 1.29
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006. Ann Rheum Dis (2006) 1.25
Blocking interleukin-1 in rheumatic diseases. Ann N Y Acad Sci (2009) 1.25
Genetic and pharmacologic disruption of interleukin-1β signaling inhibits experimental aortic aneurysm formation. Arterioscler Thromb Vasc Biol (2013) 1.23
Memory deficits induced by inflammation are regulated by α5-subunit-containing GABAA receptors. Cell Rep (2012) 1.06
The association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis: systematic review and meta-analyses. Arthritis Res Ther (2011) 1.04
Treating rheumatic patients with a malignancy. Arthritis Res Ther (2011) 1.03
Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies. Rheumatology (Oxford) (2015) 1.01
Effective treatment of a colchicine-resistant familial Mediterranean fever patient with anakinra. Ann Rheum Dis (2007) 0.99
Inflammasomes and their activation. Crit Rev Immunol (2010) 0.98
IL-1β suppresses innate IL-25 and IL-33 production and maintains helminth chronicity. PLoS Pathog (2013) 0.96
Serious infections with antirheumatic therapy: are biologicals worse? Ann Rheum Dis (2006) 0.95
Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey. Orphanet J Rare Dis (2015) 0.94
Interleukin-6 mediates epithelial-stromal interactions and promotes gastric tumorigenesis. PLoS One (2013) 0.93
Sustained intra-articular delivery of IL-1RA from a thermally-responsive elastin-like polypeptide as a therapy for post-traumatic arthritis. Eur Cell Mater (2015) 0.92
Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension. Eur Heart J (2013) 0.92
Injection-site reactions upon Kineret (anakinra) administration: experiences and explanations. Rheumatol Int (2011) 0.91
An open-label pilot study of the efficacy and safety of anakinra in patients with psoriatic arthritis refractory to or intolerant of methotrexate (MTX). Clin Rheumatol (2010) 0.90
Interleukin-1 receptor signaling is required to overcome the effects of pertussis toxin and for efficient infection- or vaccination-induced immunity against Bordetella pertussis. Infect Immun (2010) 0.89
Evasion of inflammasome activation by microbial pathogens. J Clin Invest (2015) 0.84
The IL-1 cytokine family and its role in inflammation and fibrosis in the lung. Semin Immunopathol (2016) 0.83
Hepatotoxicity due to tocilizumab and anakinra in rheumatoid arthritis: two case reports. Int J Gen Med (2011) 0.82
Critical role for IL-1β in DNA damage-induced mucositis. Proc Natl Acad Sci U S A (2014) 0.81
Binge alcohol consumption aggravates oxidative stress and promotes pathogenesis of NASH from obesity-induced simple steatosis. Mol Med (2014) 0.81
Are Th17 cells an appropriate new target in the treatment of rheumatoid arthritis? Clin Transl Sci (2010) 0.81
Efficacy and safety of anakinra for the treatment of rheumatoid arthritis: an update of the Oregon Drug Effectiveness Review Project. Biologics (2009) 0.80
Biological therapies for the treatment of juvenile idiopathic arthritis: Lessons from the adult and pediatric experiences. Biologics (2008) 0.80
Leukocyte activity in patients with ST-segment elevation acute myocardial infarction treated with anakinra. Mol Med (2014) 0.79
Mutual amplification of HNF4α and IL-1R1 composes an inflammatory circuit in Helicobacter pylori associated gastric carcinogenesis. Oncotarget (2016) 0.79
Relative contribution of IL-1α, IL-1β and TNF to the host response to Mycobacterium tuberculosis and attenuated M. bovis BCG. Immun Inflamm Dis (2013) 0.79
Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor-treated CML stem cells. Blood (2016) 0.78
Assessing infection risk with biologic agents in RA: methodological challenges. Nat Rev Rheumatol (2009) 0.78
Pharmacotherapy of scleritis: current paradigms and future directions. Expert Opin Pharmacother (2013) 0.77
Hepatotoxicity of tocilizumab and anakinra in rheumatoid arthritis: management decisions. Clin Pharmacol (2011) 0.76
IL-1 Inhibition May Have an Important Role in Treating Refractory Kawasaki Disease. Front Pharmacol (2017) 0.75
Incidence density of serious infection, opportunistic infection, and tuberculosis associated with biologic treatment in patients with rheumatoid arthritis - a systematic evaluation of the literature. Open Access Rheumatol (2013) 0.75
Biologics and heart failure in rheumatoid arthritis: are we any wiser? Curr Opin Rheumatol (2008) 0.75
Conformational Sampling and Binding Site Assessment of Suppression of Tumorigenicity 2 Ectodomain. PLoS One (2016) 0.75
Evaluation of the Interleukin-1 Receptor Antagonist and Immunoregulatory Interleukin-10 in the Middle Ear in Chronic Otitis Media With Effusion in Children With and Without Atopy. Clin Exp Otorhinolaryngol (2016) 0.75
Oxidized Low-Density Lipoprotein Immune Complex Priming of the Nlrp3 Inflammasome Involves TLR and FcγR Cooperation and Is Dependent on CARD9. J Immunol (2017) 0.75
Immunosuppressive therapy for eye diseases: Effectiveness, safety, side effects and their prevention. Taiwan J Ophthalmol (2015) 0.75
[IL-1 antagonists]. Z Rheumatol (2010) 0.75
[Risk of infection by biologics]. Z Rheumatol (2008) 0.75
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med (2000) 16.20
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med (2004) 14.53
A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med (1999) 11.62
A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med (2000) 10.21
Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum (1998) 8.69
Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med (1997) 8.65
Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum (2003) 8.50
Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med (1999) 6.84
Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum (2004) 6.22
Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum (2002) 4.69
Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst (1993) 4.59
Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum (2004) 4.57
Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum (1998) 4.37
Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum (2002) 4.15
Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2002) 3.78
Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis (2004) 3.64
Predictors of infection in rheumatoid arthritis. Arthritis Rheum (2002) 3.47
Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis. J Chronic Dis (1978) 3.08
Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra. Arthritis Rheum (1996) 2.92
Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med (1994) 2.89
Cancer morbidity in rheumatoid arthritis. Ann Rheum Dis (1984) 2.67
Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. BMJ (1998) 2.51
Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum (2004) 2.35
Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis. J Rheumatol (2001) 1.86
A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum (2000) 1.79
Prevalence of self-reported arthritis or chronic joint symptoms among adults--United States, 2001. MMWR Morb Mortal Wkly Rep (2002) 1.69
Lymphoproliferative malignancy in rheumatoid arthritis: a study of 20 cases. Ann Rheum Dis (1984) 1.66
Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial. Arthritis Rheum (2003) 1.64
Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. Ann Rheum Dis (2003) 1.64
The safety of anakinra in high-risk patients with active rheumatoid arthritis: six-month observations of patients with comorbid conditions. Arthritis Rheum (2004) 1.61
Neoplasms of the immune system in rheumatoid arthritis. Am J Med (1985) 1.52
Prevention of murine collagen-induced arthritis in the knee and ipsilateral paw by local expression of human interleukin-1 receptor antagonist protein in the knee. Arthritis Rheum (1997) 1.41
Suppression of antigen-induced arthritis in rabbits by ex vivo gene therapy. J Immunol (1996) 1.33
Frequency of infection among patients with rheumatoid arthritis versus patients with osteoarthritis or soft tissue rheumatism. Arthritis Rheum (1988) 1.18
Infectious complications of immunosuppressive therapy in patients with rheumatic diseases. Rheum Dis Clin North Am (1997) 0.98
Safety overview of new disease-modifying antirheumatic drugs. Rheum Dis Clin North Am (2004) 0.94
Concomitant medication use in a large, international, multicenter, placebo controlled trial of anakinra, a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis. J Rheumatol (2004) 0.90
Record linkage to conduct an epidemiologic study on the association of rheumatoid arthritis and lymphoma in the Province of Saskatchewan, Canada. J Clin Epidemiol (1993) 0.85
Infections in rheumatoid arthritis--a new phenomenon? J Rheumatol (2001) 0.82
Complete genome sequence of the methanogenic archaeon, Methanococcus jannaschii. Science (1996) 41.35
The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature (1997) 34.00
The complete genome sequence of the hyperthermophilic, sulphate-reducing archaeon Archaeoglobus fulgidus. Nature (1997) 14.38
A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med (2000) 10.21
Highly parallel SNP genotyping. Cold Spring Harb Symp Quant Biol (2003) 9.10
Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med (1997) 8.65
Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med (1999) 6.84
Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group. N Engl J Med (1995) 6.23
A systematic review and meta-analysis of early goal-directed therapy for septic shock: the ARISE, ProCESS and ProMISe Investigators. Intensive Care Med (2015) 4.95
Hexokinase as a sugar sensor in higher plants. Plant Cell (1997) 4.89
A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) (2003) 4.86
Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood (1997) 4.78
The role of shared receptor motifs and common Stat proteins in the generation of cytokine pleiotropy and redundancy by IL-2, IL-4, IL-7, IL-13, and IL-15. Immunity (1995) 3.99
Chromosome 2 sequence of the human malaria parasite Plasmodium falciparum. Science (1998) 3.83
European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol (2009) 3.56
Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann Rheum Dis (2002) 3.53
Weekend mortality for emergency admissions. A large, multicentre study. Qual Saf Health Care (2010) 3.45
Analysis of Arabidopsis glucose insensitive mutants, gin5 and gin6, reveals a central role of the plant hormone ABA in the regulation of plant vegetative development by sugar. Genes Dev (2000) 3.42
A three-dimensional digital atlas database of the adult C57BL/6J mouse brain by magnetic resonance microscopy. Neuroscience (2005) 3.41
The Jehovah's Witness and dementia: who or what defines 'best interests'? Anaesthesia (2006) 3.37
Effectiveness of a 'thrombolysis nurse' in shortening delay to thrombolysis in acute myocardial infarction. J R Coll Physicians Lond (1999) 3.35
Missense mutations abolishing DNA binding of the osteoblast-specific transcription factor OSF2/CBFA1 in cleidocranial dysplasia. Nat Genet (1997) 3.20
Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol (2011) 3.07
The Brn-3 family of POU-domain factors: primary structure, binding specificity, and expression in subsets of retinal ganglion cells and somatosensory neurons. J Neurosci (1995) 2.94
AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations. Proc Natl Acad Sci U S A (2001) 2.84
150 bicycle injuries in children: a comparison with accidents due to other causes. Injury (1981) 2.81
Health services research for decision-makers: the use of the Delphi technique to determine health priorities. J Health Polit Policy Law (1977) 2.79
Prediction of in-hospital mortality and length of stay using an early warning scoring system: clinical audit. Clin Med (2006) 2.63
Sugars as signaling molecules. Curr Opin Plant Biol (1999) 2.62
Crystal structure of the conserved core of protein arginine methyltransferase PRMT3. EMBO J (2000) 2.56
Campylobacteriosis in New Zealand: results of a case-control study. J Epidemiol Community Health (1997) 2.55
Physiological role of Akt in insulin-stimulated translocation of GLUT4 in transfected rat adipose cells. Mol Endocrinol (1997) 2.51
Tuberculin Testing in Children. Br Med J (1945) 2.48
POU domain factor Brn-3b is required for the development of a large set of retinal ganglion cells. Proc Natl Acad Sci U S A (1996) 2.48
A family of positive regulators related to the Pseudomonas putida TOL plasmid XylS and the Escherichia coli AraC activators. Nucleic Acids Res (1990) 2.48
A randomized controlled trial of psychotherapy in patients with chronic functional dyspepsia. Gastroenterology (2000) 2.44
Amoxicillin pharmacokinetics in pregnant women: modeling and simulations of dosage strategies. Clin Pharmacol Ther (2007) 2.38
Carbon and nitrogen sensing and signaling in plants: emerging 'matrix effects'. Curr Opin Plant Biol (2001) 2.37
Vertebrate slit, a secreted ligand for the transmembrane protein roundabout, is a repellent for olfactory bulb axons. Cell (1999) 2.35
Infection in social networks: using network analysis to identify high-risk individuals. Am J Epidemiol (2005) 2.31
Culture, risk factors and suicide in rural China: a psychological autopsy case control study. Acta Psychiatr Scand (2004) 2.24
Synovitis score: discrimination between chronic low-grade and high-grade synovitis. Histopathology (2006) 2.24
[The current structure of rheumatology in German universities. The Rhesus and RISA-II studies]. Z Rheumatol (2008) 2.21
Mutagenesis of the N-(deoxyguanosin-8-yl)-2-amino-1-methyl-6-phenylimidazo[4, 5-b]pyridine DNA adduct in mammalian cells. Sequence context effects. J Biol Chem (1999) 2.17
Malabsorption due to cholecystokinin deficiency in a patient with autoimmune polyglandular syndrome type I. N Engl J Med (2001) 2.15
Identification of p8,14 as a highly abundant heterodimeric calcium binding protein complex of myeloid cells. J Biol Chem (1991) 2.07
HIV, hepatitis C and risk behaviour in a Canadian medium-security federal penitentiary. Queen's University HIV Prison Study Group. QJM (2000) 2.06
The effect of applying NICE guidelines for the investigation of stable chest pain on out-patient cardiac services in the UK. QJM (2011) 2.02
A large carbon sink in the woody biomass of Northern forests. Proc Natl Acad Sci U S A (2001) 2.02
Toward a data-driven evaluation of the 2010 American College of Rheumatology/European League Against Rheumatism criteria for rheumatoid arthritis: is it sensible to look at levels of rheumatoid factor? Arthritis Rheum (2011) 2.01
Association between glutathione S-transferase M1, P1, and T1 genetic polymorphisms and development of breast cancer. J Natl Cancer Inst (1998) 1.97
Competence for genetic transformation in Streptococcus pneumoniae: organization of a regulatory locus with homology to two lactococcin A secretion genes. Gene (1995) 1.94
Diet, physical activity, and colorectal cancer among Chinese in North America and China. J Natl Cancer Inst (1990) 1.92
Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics (1997) 1.92
Rates of and risk factors for trichomoniasis among pregnant inmates in New York City. Sex Transm Dis (1998) 1.92
Analysis of the role of AML1-ETO in leukemogenesis, using an inducible transgenic mouse model. Blood (2000) 1.91
Brn-3b: a POU domain gene expressed in a subset of retinal ganglion cells. Neuron (1993) 1.88
Essential role of POU-domain factor Brn-3c in auditory and vestibular hair cell development. Proc Natl Acad Sci U S A (1997) 1.88
Is Clostridium difficile endemic in chronic-care facilities? Lancet (1986) 1.88
Two hundred glass injuries. Arch Dis Child (1984) 1.87
The mouse SLIT family: secreted ligands for ROBO expressed in patterns that suggest a role in morphogenesis and axon guidance. Dev Biol (1999) 1.87
Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis. J Rheumatol (2001) 1.86
Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis (2002) 1.85
Current European concepts in the management of Helicobacter pylori infection--the Maastricht Consensus Report. The European Helicobacter Pylori Study Group (EHPSG). Eur J Gastroenterol Hepatol (1997) 1.81
Structure of human DNMT2, an enigmatic DNA methyltransferase homolog that displays denaturant-resistant binding to DNA. Nucleic Acids Res (2001) 1.81
PPARgamma activation induces the expression of the adipocyte fatty acid binding protein gene in human monocytes. Biochem Biophys Res Commun (1999) 1.76
Heterodimers of placenta growth factor/vascular endothelial growth factor. Endothelial activity, tumor cell expression, and high affinity binding to Flk-1/KDR. J Biol Chem (1996) 1.75
Neuropsychiatric problems in systemic lupus erythematosus. Br Med J (1972) 1.74
The pattern of disulfide linkages in the extracellular loop regions of connexin 32 suggests a model for the docking interface of gap junctions. J Cell Biol (1998) 1.73
CBFA1 mutation analysis and functional correlation with phenotypic variability in cleidocranial dysplasia. Hum Mol Genet (1999) 1.72
Optimal screening mammography reading volumes; evidence from real life in the East Midlands region of the NHS Breast Screening Programme. Clin Radiol (2010) 1.72
A cost-benefit analysis of culling badgers to control bovine tuberculosis. Vet J (2006) 1.72
Sex steroids and bone mass in older men. Positive associations with serum estrogens and negative associations with androgens. J Clin Invest (1997) 1.72
Targeted deletion of the mouse POU domain gene Brn-3a causes selective loss of neurons in the brainstem and trigeminal ganglion, uncoordinated limb movement, and impaired suckling. Proc Natl Acad Sci U S A (1996) 1.71
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis (2007) 1.70
CUL-2 is required for the G1-to-S-phase transition and mitotic chromosome condensation in Caenorhabditis elegans. Nat Cell Biol (1999) 1.69
Acceleration of wound healing by topical application of honey. An animal model. Am J Surg (1983) 1.66
Effects of female relative support in labor: a randomized controlled trial. Birth (1999) 1.62
Combination treatment of severe rheumatoid arthritis with cyclosporine and methotrexate for forty-eight weeks: an open-label extension study. The Methotrexate-Cyclosporine Combination Study Group. Arthritis Rheum (1997) 1.61
The quaking I-5 protein (QKI-5) has a novel nuclear localization signal and shuttles between the nucleus and the cytoplasm. J Biol Chem (1999) 1.59
Analgesic nephropathy. Clinical course after withdrawal of phenacetin. Br Med J (1969) 1.58
Invertebrate responses to the management of genetically modified herbicide-tolerant and conventional spring crops. I. Soil-surface-active invertebrates. Philos Trans R Soc Lond B Biol Sci (2003) 1.57
Deletions spanning the neurofibromatosis 1 gene: identification and phenotype of five patients. Am J Hum Genet (1994) 1.56
P(0) glycoprotein overexpression causes congenital hypomyelination of peripheral nerves. J Cell Biol (2000) 1.55
A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer. Ann Oncol (1998) 1.53
Biological consequences of thrombin receptor deficiency in mice. Thromb Haemost (1996) 1.53
Aromatic DNA adducts in foundry workers in relation to exposure, life style and CYP1A1 and glutathione transferase M1 genotype. Carcinogenesis (1997) 1.53
Platelet lipid(s) bound to albumin increases endothelial electrical resistance: mimicked by LPA. Am J Physiol Lung Cell Mol Physiol (2001) 1.53
Lumbosacral joint angles in children. J Pediatr Orthop (1992) 1.52
Adherence to antiviral drug regimens in HIV-infected adolescent patients engaged in care in a comprehensive adolescent and young adult clinic. J Natl Med Assoc (2000) 1.52
Chloroquine as a malarial suppressive: absence of visual effects. Mil Med (1973) 1.51
A fluorescence energy transfer method for analyzing protein oligomeric structure: application to phospholamban. Biophys J (1999) 1.50
Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. Ann Rheum Dis (2008) 1.49
Mature dendritic cells infiltrate the T cell-rich region of oral mucosa in chronic periodontitis: in situ, in vivo, and in vitro studies. J Immunol (2001) 1.49
Construction and analysis of compact muscle-specific promoters for AAV vectors. Gene Ther (2008) 1.48
Serotonin 5-HT(2C) receptors regulate anxiety-like behavior. Genes Brain Behav (2007) 1.48
New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor alpha antagonists. Ann Rheum Dis (2005) 1.47
Dichotomy of AML1-ETO functions: growth arrest versus block of differentiation. Mol Cell Biol (2001) 1.46